Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind? Hosted by: Warner Huh, MD, Deputy Editor of Gynecologic Oncology Featuring: Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics a...